Home PFE
43.76
  Price0.68%   -0.30
(After Hours: 43.85 +0.09 +0.21% )
loading

Pfizer, Inc. (PFE) Latest News

Feb-06-23 06:20AM 5 Stocks That Moved the Market in JanuaryThe Motley Fool
05:41AM Is Gilead Sciences a Good Stock to Buy Now?The Motley Fool
Feb-06-23 02:12AM Biogen: What To Do Ahead Of Q4 2022 Financial ReportSeeking Alpha
Feb-03-23 02:15AM Retirees: Don't fall for a popularity contest when it comes to your investmentsMarketWatch
01:35AM Top 5 Health Care Stocks That May RallyBenzinga
Feb-03-23 09:19AM Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?The Motley Fool
09:19AM Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc LawsuitsZacks Investment Research
Feb-02-23 11:04AM Economic Data DelugeZacks Investment Research
10:39AM Goldilocks Econ Data Presides Over Pre-MarketZacks Investment Research
Feb-02-23 07:54AM Got $1,000? 3 Cheap Stocks To Buy Right NowThe Motley Fool
06:10AM This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 YearsThe Motley Fool
Feb-02-23 05:50AM Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.The Motley Fool
Feb-01-23 09:20AM Company News for Feb 1, 2023Zacks Investment Research
08:43AM Biden to end U.S. COVID emergencies on May 11, but more than 500 people are still dying every dayMarketWatch
Feb-01-23 08:10AM AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For WednesdayBenzinga
06:11AM S&P 500 Jumps 1.5%, Market Volatility DecreasesBenzinga
Feb-01-23 06:00AM 1 Reason to Buy Novavax in 2023 and 2 Reasons to SellThe Motley Fool
03:54AM Pfizer (PFE) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research
Feb-01-23 12:58PM Pfizer Inc. 2022 Q4 - Results - Earnings Call PresentationSeeking Alpha
Jan-31-23 07:00AM Pfizer (PFE) Q4 2022 Earnings Call TranscriptThe Motley Fool
04:40AM Nasdaq books best January since 2001 as U.S. stocks post strong monthly gains ahead of Fed decisionMarketWatch
Jan-31-23 03:11AM Dow rises over 200 points as U.S. stocks climb, aiming for strong January finishMarketWatch
02:41AM What Happens This Week Will Lead the Market for 2023Zacks Investment Research
Jan-31-23 02:36AM Dow Surges Over 200 Points; Pfizer Issues Weak ForecastBenzinga
01:16AM Pfizer’s COVID revenues have dropped off along with attention to the pandemic MarketWatch
Jan-31-23 12:26PM Biden to end U.S. COVID emergencies on May 11, but more than 500 people are still dying every dayMarketWatch
12:04PM U.S. stocks climb, aiming for strong January finish, as Fed decision awaitsMarketWatch
Jan-31-23 11:14AM U.S. stocks trade higher, heading for strong January finish, as Fed decision awaitsMarketWatch
11:06AM Employment Cost Index Comes in Lowest Since Q4 2021Zacks Investment Research
Jan-31-23 11:00AM Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top StoriesBenzinga
10:49AM Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock DownZacks Investment Research
Jan-31-23 10:45AM Biden to end U.S. COVID emergencies on May 11, but more than 500 people are still dying every dayMarketWatch
10:37AM Best January in 4 Years Heads for Its Close; XOM, CAT, GM & More ReportZacks Investment Research
Jan-31-23 10:03AM U.S. stocks trade higher, heading for strong January finish, as Fed decision awaitsMarketWatch
09:14AM U.S. stock futures gain to cap strong January for Wall Street, with Fed decision aheadMarketWatch
Jan-31-23 09:09AM This newsletter editor has been recommending stocks and bonds this year and says the rally has room to runMarketWatch
08:50AM Biggest Earnings Week of the Season: Key Stocks to WatchZacks Investment Research
Jan-31-23 08:34AM This newsletter editor has been recommending stocks and bonds this year and says the rally has room to runMarketWatch
08:15AM Pfizer (PFE) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research
Jan-31-23 08:02AM 4 Discounted Dividend Stocks To Buy In February 2023The Motley Fool
06:53AM This newsletter editor has been recommending stocks and bonds this year and says the rally has room to runMarketWatch
Jan-31-23 06:47AM These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate AnalystsBenzinga
06:37AM Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good TimesBenzinga
Jan-31-23 04:01AM General Motors, McDonald's And 3 Stocks To Watch Heading Into TuesdayBenzinga
03:02AM Investor Optimism Declines Ahead Of Fed's Rate DecisionBenzinga
Jan-30-23 04:00AM Down 14.5%, Is Pfizer Stock a Screaming Buy?The Motley Fool
05:00AM The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and NovavaxZacks Investment Research
Jan-27-23 01:52AM FDA panel backs plan for annual COVID-19 booster, as new omicron subvariant continues to dominate in new casesMarketWatch
11:28AM Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?Zacks Investment Research
Jan-27-23 11:18AM FDA panel backs plan for annual COVID-19 booster, as new omicron subvariant continues to dominate in new casesMarketWatch
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; and Zenith Epigenetics Ltd., as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.
Cap:    |  Volume (24h):